ClariCELL™ LCK Kinase Assay Service

Description

The ClariCELL™ LCK Kinase Assay quantifies autophosphorylation of human full-length LCK in human cells. The assay is useful to determine potencies of small-molecule inhibitors against the specified kinase in the context of a cellular environment. Compound testing services are available utilizing the assay.

Overview

Human Embryonic Kidney (HEK 293) cells transiently expressing sequence verified human full-length LCK are exposed to test compound or control, then lysed to release cellular proteins. LCK is captured onto an assay plate, and the extent of autophosphorylation is quantified by ELISA using an antibody specific for the phosphorylation event. Cells expressing kinase deficient LCK [K273M] are also utilized as controls to calculate the % inhibition of test compounds.

Assay Validation

LCK Expression in Cells



Figure 1: Wild type (wt) or kinase dead (K273M) LCK was expressed transiently in 293 cells. Following cell lysis, an IP Western was performed with appropriate antibodies to capture and detect total LCK1 protein.

LCK Autophosphorylation in Cells



Figure 2: Wild type (wt) or kinase dead (K273M) LCK was expressed transiently in 293 cells. Following cell lysis, an IP Western was performed with appropriate antibodies to capture and detect phospho-LCK protein.

Quantification of Phosphorylation



Figure 3: Wild type (WT) or kinase dead (K273M) LCK was expressed transiently in 293 cells. Following cell lysis, an ELISA was performed to quantify the extent of auto-phosphorylation of LCK.

Reference Inhibitor Data



Figure 4: An autophosphorylation assay was performed in the presence of dasatanib, an LCK inhibitor, and sorafenib, a compound that is not expected to inhibit LCK. % inhibition data were plotted to determine EC50s.